Company: HUM
Filing Date: 2025-03-04
Form Type: 424B5
Source: 0001628280-25-009923
Chunk: 0

Company: HUMANA INC
Filing Date: 2025-03-04
Form: 424B5
Chunk 0
---
#### Filed Pursuant to Rule 424(b)(5)

#### Registration No. 333-277734

#### Prospectus Supplement

#### March 3, 2025
(To Prospectus dated March 7, 2024)

<div align='center'>$1,250,000,000</div>

#### Humana Inc.
<div align='center'>$750,000,000 5.550% Senior Notes due 2035

$500,000,000 6.000% Senior Notes due 2055</div>

The 2035 notes will bear interest at 5.550% per year and the 2055 notes will bear interest at 6.000% per year. Interest on the 2035 notes and the 2055 notes will be payable on May 1 and November 1 of each year, beginning on November 1, 2025. The 2035 notes will mature on May 1, 2035 and the 2055 notes will mature on May 1, 2055. We refer to the 2035 notes and the 2055 notes collectively as the notes. Interest on notes will accrue from March 5, 2025. At our option, we may redeem the notes, in whole or in part, before their maturity date at the applicable redemption prices described in this prospectus supplement under the caption “Description of the Notes—Optional Redemption.” If a change of control triggering event as described in this prospectus supplement occurs, unless we have exercised our option to redeem the notes, we will be required to offer to repurchase the notes at the price described in this prospectus supplement under the caption “Description of the Notes—Offer to Repurchase Upon Change of Control Triggering Event.”

The notes will be our unsecured senior obligations and will rank equally with all of our other existing and future unsecured senior indebtedness.

Investing in the notes involves risks that are described in the “

#### Risk Factors

#### ” sections beginning on page

#### S- 4
of this prospectus supplement and in other documents incorporated by reference in this prospectus supplement and the accompanying prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

|                                           |     | Per 2035 Note |        |   |    |     | Total |             |     |